The sales for Modulators of the Genital System and Sex Hormones in Italy are forecasted to decrease from $149.4 million in 2024 to $139.4 million by 2028, exhibiting a consistent year-on-year decline. Assuming 2023 figures were stable or slightly higher around $150 million, the market shows a downward trend with an average annual contraction over these years, likely due to mature market saturation, healthcare reimbursement policies, or patient preference shifts. This results in a compound annual growth rate (CAGR) reflecting a negative trajectory over the next five years.

Future trends to watch for include:

Developments in alternative therapies or healthcare reform could influence demand.
Technological advancements or new product launches might reinvigorate the market.
Socio-cultural changes impacting usage patterns and acceptance could affect market dynamics.
Regulatory adjustments and pricing strategies remain critical in shaping market contours.